<DOC>
	<DOCNO>NCT01059682</DOCNO>
	<brief_summary>This multicenter , double-blind , randomize , placebo-controlled study evaluate effect dalcetrapib 600 mg artherosclerotic disease progression , lipid profile biomarker profile long-term safety profile dalcetrapib patient coronary artery disease . Atherosclerotic disease progression measure 1 . Coronary Intravascular Ultrasound ( IVUS ) , Quantitative Coronary Angiography 2 . Carotid B-Mode Ultrasound Intima Medial Thickness ( IMT ) total plaque volume subject undergoing coronary angiography coronary artery disease ( CAD ) . Patients randomize receive dalcetrapib 600 mg orally day placebo . The anticipated time study treatment 24 month . The target sample size 800-1000 patient .</brief_summary>
	<brief_title>A Study Effect Dalcetrapib Artherosclerotic Disease Patients With Coronary Artery Disease</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Dalcetrapib</mesh_term>
	<criteria>Adult patient age 18 year Angiographic evidence coronary artery disease Ultrasound evidence carotid artery disease Treated appropriately dyslipidemia Previous exposure cholesteryl ester transfer protein ( CETP ) inhibitor CETPvaccine within last 3 month study start Previous coronary artery bypass graft surgery ( CABG ) probable need CABG next 24 month Myocardial infarction target coronary artery IVUS initial IVUS examination randomization Patients symptomatic congestive heart failure baseline ( New York Heart Association class III IV ) Severe anemia Uncontrolled hypertension Poorly control diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>